Kuznicki Law is investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR). Under the terms of the proposed transaction, shareholders of Miromatrix will receive $3.25 in cash for each share of Miromatrix that they own, as well as an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s kidney product known as mirokidney™ by December 31, 2025. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the merger is structured as a tender offer, such that time may be of the essence.